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Abstract
Introduction Mass spectrometry is the current technique of
choice in studying drug metabolism. High-resolution mass
spectrometry in combination with MS/MS gas-phase
experiments has the potential to contribute to rapid
advances in this field. However, the data emerging from
such fragmentation spectral files pose challenges to
downstream analysis, given their complexity and size.
Objectives This study aims to detect and visualize anti-
hypertensive drug metabolites in untargeted metabolomics
experiments based on the spectral similarity of their frag-
mentation spectra. Furthermore, spectral clusters of
endogenous metabolites were also examined.
Methods Here we apply a molecular networking approach
to seek drugs and their metabolites, in fragmentation
spectra from urine derived from a cohort of 26 patients on
antihypertensive therapy. The mass spectrometry data was
collected on a Thermo Q-Exactive coupled to pHILIC
chromatography using data dependent analysis (DDA) MS/
MS gas-phase experiments.
Results In total, 165 separate drug metabolites were found
and structurally annotated (17 by spectral matching and
122 by classification based on a clustered fragmentation
pattern). The clusters could be traced to 13 drugs including
the known antihypertensives verapamil, losartan and
amlodipine. The molecular networking approach also
generated clusters of endogenous metabolites, including
carnitine derivatives, and conjugates containing glutamine,
glutamate and trigonelline.
Conclusions The approach offers unprecedented capability
in the untargeted identification of drugs and their metabo-
lites at the population level and has great potential to
contribute to understanding stratified responses to drugs
where differences in drug metabolism may determine
treatment outcome.
Keywords Antihypertensive drugs  Drug adherence 
Drug metabolism  Fragmentation  High-resolution mass
spectrometry  Metabolomics  Urine
1 Introduction
Mass spectrometry is pre-eminent in the analysis of drug
metabolism. The enhanced sensitivity of new generation
mass spectrometers including the high-resolution Orbitrap
series of instruments (Zubarev and Makarov 2013) pro-
vides ever more capability to understand how drugs are
metabolised by the human body. Mass spectrometry frag-
mentation (MS/MS or MS2) is widely used to find drug
specific fragments (Levsen et al. 2005; Zhang et al. 2009;
Gao et al. 2015) but the complexity of the data offers
significant analytical challenges (Garg et al. 2015) and
tools enabling advanced spectral analysis offer great utility
in deriving new knowledge from this data (Hufsky et al.
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2014; Ridder et al. 2014; Misra and van der Hooft 2016).
Some of these tools will be discussed in the next
paragraphs.
The mass defect filtering (MDF) approach is one
example used to target drug derived metabolites within a
complex extract (Zhu et al. 2006). The MDF approach uses
drugs and core template filters and a set of commonly
found transformations in drug metabolism such as
hydroxylation, methylation, and decarboxylation and their
calculated ‘mass defect shifts’, i.e., the fractional differ-
ence of the reactant and the product. With these filters and
mass defects, potential drug metabolites can be found
within a larger set of detected compounds in high-resolu-
tion mass spectrometry (HR-MS) data combined with data-
dependent analysis (DDA) fragmenting the most abundant
ions (i.e., the TopN ions) entering the mass spectrometer.
More recently, the MS2Analyzer tool was developed to
screen for specific product ions (mass fragments), neutral
losses (difference between precursor ion and a product
ion), and mass differences (difference between two product
ions) in (HR-MS) fragmentation data (Ma et al. 2014). In
principle, MS2Analyzer can be used to screen for spectra
that contain pre-determined drug product ions, as well as
commonly found losses caused by biotransformation of
drugs, such as glucuronidation (i.e., 176.0321 Da) and
sulfation (i.e., 79.9568 Da), which can be added into the
search to aid in metabolite annotation.
Both of the above tools require specific user input to get
meaningful results, including: (i) a list of expected drugs
with their elemental formulas to determine their theoretical
masses in the relevant ionization mode or (ii) mass spectral
fragmentation data of drugs, whether experimental or in
silico, to determine their specific product ions or neutral
losses. This structural information is usually obtained from
spectral libraries or previously characterised compounds.
Currently, mass spectral libraries contain only a small
fraction of the metabolites whose existence is known; for
example, mzCloud (www.mzCloud.org) and MassBank
(www.massbank.jp) contain fragmentation spectra of
thousands of compounds, whereas PubChem (http://www.
ncbi.nlm.nih.gov/pccompound) contains tens of millions of
chemical structures (da Silva et al. 2015; Vinaixa et al.
2015) and many other compounds have yet to be cata-
logued in any database. Several computational tools that
predict metabolite structures and fragmentation patterns in
silico are in development (Hufsky et al. 2014; Ridder et al.
2014), but most are currently not capable of global anal-
yses or comparison of large numbers of fragmentation
spectra.
There is generally no a priori knowledge of all
metabolite classes that will appear in untargeted metabo-
lomics experiments, and in an era of precision and stratified
medicine, comparing metabolic potential between
individuals is of increasing importance. Therefore, tools
that can compare and visualize large amounts of spectral
data in an unbiased manner, i.e., without prior structural
information, are needed. For example, molecular net-
working performs clustering of similar MS2 spectra from
natural product extracts (Watrous et al. 2012; Yang et al.
2013). The tool compares MS2 fragmentation spectra in an
unsupervised manner using cosine scoring on vectorised
MS2 spectra. As a result, similar spectra are combined in a
network node represented by a consensus spectrum. Nodes
showing a degree of cross-node similarity are then con-
nected by edges again based on cosine similarity scoring. If
one or a few of the nodes in the network have a match to
spectral databases present within the GNPS environment
(http://gnps.ucsd.edu), such as MassBank (Horai et al.
2010), this can aid the structural annotation of closely
associated nodes based on spectral similarity (Yang et al.
2013).
Few metabolomics studies have yet reported on the use
of molecular networking combined with high-resolution
metabolomics data to aid in spectral analysis of the large
amount of spectral information resulting from data-de-
pendent fragmentation. In this study, we used human urine
extracts from a clinical cohort that encompassed patients
who were receiving combinations of antihypertensive
drugs comprised of different drug classes, including cal-
cium channel blockers, ACE inhibitors, and beta blockers.
The available meta-data was used to select urine extracts of
26 patients taking two or more different antihypertensive
drug classes. The aim of this study was to examine if the
combination of the molecular networking approach with
(HR-MS) metabolomics fragmentation data would enable
detection and visualization of clusters of antihypertensive
and other drug related metabolites from human urine
extracts.
The data shows that multiple drugs and a range of
associated metabolites can be found in urine with no a
priori knowledge of their presence. In addition, endogenous
urine metabolites also form several clusters. The combined
analysis offers new ways to assess the presence and
metabolism of drugs in individual patients, and the influ-
ence of the patient’s metabolome on drug metabolism and
the drug treatment outcome.
2 Materials and methods
2.1 Materials
2.1.1 Urine samples
Urine samples from anonymized human volunteers were
used from a clinical sample set in the Glasgow Polyomics
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archive. These samples were obtained as part of a trial for
which ethical approval was applied for through the Multi-
centre Research and Ethics Committee (MREC), which
was granted by the Scottish MREC and (with MREC N06/
MRE00/106). Informed consent was obtained from all
individual study participants. Spot urine samples were
obtained from the cohort of elderly hypertensive patients
upon their first admission in the clinic. Urine extracts of 26
patients were selected as follows: diagnosed with hyper-
tension, taking in a variety of different antihypertensive
drugs (i.e., different drug classes), and availability of the
sample extract in the Glasgow Polyomics archive. The
resulting subject’s age range spanned from 42 to 87; 15
were male, 11 female; 4 were smokers; 5 were reported to
have diabetes; and each reportedly took from 2 to 7 dif-
ferent classes of antihypertensive drugs. All recorded
details of the patients can be found in the Supplementary
Information (Supplementary Table S1).
2.1.2 Chemicals
HPLC-grade methanol, acetonitrile, isopropanol, and ana-
lytical reagent grade chloroform were acquired from Fisher
Scientific, Loughborough, UK. HPLC grade H2O was
purchased from VWR Chemicals, Fountenay-sous-Bois,
France. Formic acid (for mass spectrometry) and ammo-
nium carbonate were acquired from Fluka Analytical
(Sigma Aldrich), Steinheim, Germany.
2.2 Methods
2.2.1 Urine sample preparations
A general metabolome extraction procedure was per-
formed (Creek et al. 2011): (i) 5 lL urine was extracted
in 200 lL chloroform/methanol/water (1:3:1) at 4 C; (ii)
then vortexed for 5 min at 4 C; (iii) then centrifuged for
3 min (13,000 g) at 4 C. The resulting supernatant was
stored at -80 C until analysis. A pooled aliquot of the
26 selected urine samples was prepared prior to the LC–
MS runs with DDA applying higher collision dissociation
(HCD)
2.2.2 Analytical platform
A Thermo Scientific Ultimate 3000 RSLCnano liquid
chromatography system (Thermo Scientific, CA, USA) was
used. That system was coupled to a Thermo Scientific
Q-Exactive Orbitrap mass spectrometer equipped with a
HESI II interface (Thermo Scientific, Hemel Hempstead,
UK). Thermo Xcalibur Tune software (version 2.5) was
used for instrument control and data acquisition.
2.2.3 LC settings
The HILIC separation was performed with a SeQuant ZIC-
pHILIC column (150 9 4.6 mm, 5 lm) equipped with the
corresponding pre-column (Merck KGaA, Darmstadt,
Germany). A linear biphasic LC gradient was conducted
from 80 % B to 20 % B over 15 min, followed by a 2 min
wash with 5 % B, and 7 min re-equilibration with 80 % B,
where solvent B is acetonitrile and solvent A is 20 mM
ammonium carbonate in water. The flow rate was 300 lL/
min, column temperature was maintained at 25 C, injec-
tion volume was 10 lL, and samples were maintained at
4 C in the autosampler (Creek et al. 2011).
2.2.4 MS and MS/MS settings
Positive negative ionization combined fragmentation mode
a duty cycle consisted of a full scan in positive ionization
mode, followed by a TopN MS/MS (MS2) data dependent
fragmentation event, taking the 10 most abundant ion
species not on the dynamic exclusion list, followed by the
same two scan events in negative ionization mode. Data
acquisition was carried out in positive (?) and negative (-)
switching ionization mode, using m/z 74.0964 (?) (ACN
cluster), 88.07569 (?) (contaminant), and m/z 112.98563
(-) (Formic Acid cluster) as lock masses. The set up was
calibrated [Thermo calmix (PierceTM calibration solutions
from Thermo Scientific), with additional masses at lower
m/z; 74.0964 m/z (?) and 89.0244 (-)] in both ionization
modes before analysis and a tune file targeted towards the
lower m/z range was used.
Unless specified differently, full scan (MS1) data was
acquired in both ionization modes in profile mode at 35,000
resolution (at m/z 200) using 1 microscan, an AGC target of
106 cts, a maximum injection time of 120 ms, with spray
voltages ?3.8 and -3.0 kV, capillary temperature 320 C,
sheath gas flow rate 40, auxiliary gas flow rate 15 a.u., sweep
gas flow rate 1 a.u, and a full scan mass window of
70–1050 m/z.
MS/MS (MS2) data was acquired in profile mode at
35,000 resolution using 1 microscan, an AGC target of
1 9 105 cts, a maximum injection time of 120 ms, a loop
count of 10, a MSX count of 1, a TopN of 10, an isolation
window of 1.0 Da, an isolation offset of 0.0 Da, a stepped
normalized collision energy (NCE) (HCD) mode combin-
ing 25.2, 60.0, and 94.8 NCEs into one fragmentation scan,
an underfill ratio of 20 %, an intensity threshold of
1.7 9 105 cts, and the dynamic exclusion was set to 15 s.
Further settings were: no apex trigger, no charge exclusion,
peptide match was off, exclude isotopes was on, and if idle,
the setting ‘the machine does not pick up other ions’ was
chosen.
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Positive or negative ionization separate fragmentation
modes as for the combined experiments, with the following
modifications: full scan (MS1) resolution (at m/z 200) was
set to 70,000, MS/MS (MS2) resolution (at m/z 200) was
set to 17,500, MS/MS maximum injection time was set to
80 ms and the underfill ratio set to 10 %, with a resulting
intensity threshold of 1.3 9 105 cts. The duty cycle con-
sisted of one full scan (MS1) event and one Top10 MS/MS
(MS2) fragmentation event.
Positive negative ionization combined full scan mode as
for the combined experiments, with the following modifi-
cations: full scan (MS1) resolution (at m/z 200) was set to
70,000. The duty cycle consisted of two full scan (MS1)
events.
2.3 Data acquisition and processing
2.3.1 Data acquisition
Blank runs, quality control samples (beer and serum
extracts in accordance with standard procedures at
Glasgow Polyomics) to assess the performance of the
mass spectrometer in terms of chromatography and mass
intensities, and three standard mixes containing 150
reference compounds were run to assess the quality of
the mass spectrometer and to aid in metabolite annota-
tion and identification (Creek et al. 2011). The pooled
sample was run prior to and across the batch every 6th
sample to monitor the stability and quality of the LC–
MS run, whereas the samples were run in a randomized
order.
Immediately after acquisition, all raw files were con-
verted into mzXML format, thereby centroiding the mass
spectra and separating positive and negative ionization
mode spectra into two different mzXML files using the
command line version of MSconvert (ProteoWizard).
Accurate masses of standards were obtained well within
3 ppm accuracy and intensities of the quality control
samples (a beer extract and a serum extract) were within
specifications.
All 26 urine extracts were run in the combined frag-
mentation mode, a subset of 12 urine extracts underwent
the separate fragmentation modes collecting fragmentation
data for both modes in two separate files, and a subset of 6
urine extracts were run in combined full scan mode using
three replicate injections. A number of separate fragmen-
tation mode files were run as part of another batch; how-
ever, only small retention time drifts were observed (within
0.15 min) and the comparison does not use retention time
information, as it is based on MS2 spectral similarity. See
Supplementary Table 1 for detailed information where it is
specified for each urine extract which modes were
recorded.
2.3.2 Data processing
The data processing and data analysis steps are summa-
rized in a flowchart (see Fig. 1).The mzXML files were
uploaded into the Global Natural Products Social Molec-
ular Networking (GNPS) environment (http://gnps.ucsd.
edu—a free account is needed to log in) using an FTP
server (FileZilla, version 3.10.1.1). Parameter optimization
for molecular network generation for the (HR-MS) data
sets resulted in the following settings. All MS2 spectra
present in the data were clustered with MS-Cluster with a
so-called ‘parent mass tolerance’ of 0.25 Da and a MS/MS
fragment ion tolerance of 0.005 Da to create consensus
spectra. Then, consensus spectra that contained less than 2
spectra were discarded. A network was created where
edges were filtered to have a cosine score above 0.55 and 2
or more matched peaks. Further edges between two nodes
were kept in the network only if each of the nodes appeared
in each others respective top 10 most similar nodes. The
spectra in the network were then searched against the
GNPS spectral libraries. The library spectra were filtered in
the same manner as the input data. All matches kept
between network spectra and library spectra were required
to have a cosine score above 0.6 and at least 4 matched
peaks. Analog search was enabled against the library with a
maximum mass shift of 100.0 Da. All parameters and their
values used can be found in Supplementary Table S2.
Running times were under 15 min for both combined and
Extracted urine samples
Orbitrap
Mass Spectrometry
Raw files are directly 
converted into 
mzXML format
mzXML files are 
uploaded to GNPS –
where spectral 
clustering, molecular 
network formation, 
and spectral matching 
take place
Drug cluster nodes 
are validated and 
annotated 
Cytoscape input files are 
downloaded to visualize and 
inspect molecular network
Fig. 1 Flowchart explaining the different steps in data generation,
processing, and analysis to enable the annotation of drug clusters and
drug metabolites from a molecular network obtained from urine
extracts
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single mode fragmentation files. Cytoscape, network
visualization software (http://www.cytoscape.org/), was
then used to further process and visualize the downloaded
molecular network data. The recommended graphical lay-
out style is FM3 which is available for Cytoscape versions
2.8.1 and below. Thus, the molecular network was uploa-
ded into Cytoscape (version 2.8.1) following the docu-
mentation available on the GNPS website. After applying
the FM3 layout plugin, the molecular network was saved
in.cys format (Cytoscape Session File) and reopened in
Cytoscape version 3.2.0, where labelling and colouring of
nodes and edges was conducted. Most importantly, the
nodes were labelled with precursor masses, and coloured
such that two nodes have the same colour when they are
present in the same set of files (using the rainbow pallet),
and accordingly, two nodes having similar colours means
that they are present in a similar set of files, often differing
in one or two files). Finally, the size of the nodes was made
proportional to the number of unique files from where the
node spectra originated, i.e., the larger the node, the more
unique files its spectra originated from. The edges were
labelled with the mass differences between the two nodes
they connect. The resulting molecular networks for the
combined and separate fragmentation modes were then
inspected in the Cytoscape environment.
2.4 Data analysis
2.4.1 Molecular network inspection
The first step of the molecular network analysis was to
identify drug related clusters, which we define as subsets of
connected nodes in the molecular network that all relate to
one parent drug (or endogenous compound class in case of
non-drug compounds). The resulting molecular network
was checked by initial library matches to the spectral ref-
erence data present in the databases within the GNPS
environment. Clusters containing drug annotations were
then selected and the individual nodes and edges were
inspected, as well as the cluster topology.
2.4.2 Cluster annotation
These drug related clusters were annotated using the library
matching of GNPS to MassBank and the FDA_library as a
starting point, resulting in so-called ‘seed nodes’ (Yang
et al. 2013). If a drug related metabolite was matched from
any of the libraries present in the GNPS environment, the
cluster was further inspected. Clusters with a topology
similar to the seven ‘GNPS-annotated drug clusters’ were
annotated using spectral search in MzCloud of the most
abundant MS2 spectrum belonging to the node represented
in the highest number of different urine extracts. In
addition, MAGMa was used to generate potential candi-
dates if no successful spectral match was found. Endoge-
nous urinary metabolite networks were annotated based on
‘seed node annotations’ or spectral matching of node
spectra to MzCloud. Since the primary aim of this manu-
script was to examine drug metabolites in the urine
extracts, no further individual annotations on endogenous
clusters were conducted.
2.4.3 Validation of molecular nodes
A node in the molecular network is a set of MS2 spectra
each with a cosine similarity score of 0.95 or higher to each
other (Yang et al. 2013) hence, this means that spectra of
several isomers or very related compounds could be com-
bined in one node. If such a situation occurs, the retention
time associated with the node will become the average RT
of the different MS2 spectra associated and as a result will
have a relatively large retention time deviation recorded for
it. In addition, nodes can represent isotopes, in-source
fragments, or adducts of ‘real metabolites’, as no feature
grouping is currently performed during the molecular net-
working. Thus, the nodes in the cluster need to be validated
in the raw data by checking the number of metabolites
represented by the node. Additionally, the most likely
elemental formula was assigned and a theoretical mass was
determined. Then, based on the validated metabolite
spectra, recurring product ions were noted (see Supple-
mentary Table 4) and used to mine the urine extracts by
extracted ion chromatograms of those fragment masses. If
they co-occurred in the spectrum, the precursor ion mass
was checked against the list of already annotated metabo-
lites–and added if it was absent. All drug related clusters
prior to validation are presented in the Supplementary
Information (see Sect. 2 in Supplementary Materials,
Supplementary Figs. S2, S3, S4, S5, S6, S7, S8, S9, S10,
S11, S12, S13, S14, and S15); in the other figures the nodes
representing non-drug metabolites (e.g. isotopes or frag-
ments of other nodes) were omitted from the cluster and
colours and labelling were adapted to improve readability.
2.4.4 Metabolite annotation
The drug metabolites were annotated using the library
matching, MzCloud database, and by searching for existing
drug spectra in Massbank of North America (MoNa, http://
mona.fiehnlab.ucdavis.edu/#/). Metabolite annotations are
reported according to the Metabolomics Standards Initia-
tive (MSI) metabolite identification (MI) levels: (1) for
unambiguously identified, (2) for a spectral or literature
match, (3) for a metabolite classification, (4) for metabo-
lites that can be characterized by a retention time, mass,
and fragmentation spectra if available (Sumner et al. 2007).
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Thus, if a reliable spectral match was found, the identifi-
cation level was recorded as 2, if no match was found but a
plausible elemental formula, drug specific product ions,
and a likely annotation could be assigned, e.g., hydroxy-
lated form of parent drug, the identification level was put to
3. MSI MI level 4 was given to those metabolites where the
drug specific product ions were present, but no likely ele-
mental formula or annotation could be assigned, or where
the recurring product ions could not be assigned to a unique
drug-related core structure metabolized by the human
body. All structural information obtained was recorded in
Supplementary Table S3.
3 Results
3.1 Molecular networking to discover drug related
metabolite clusters
Unsupervised large-scale comparison of (HR-MS) frag-
mentation spectra was conducted on data files from urine
extracts suspected to contain antihypertensive drug
metabolites. The resulting networks were analysed to find
potential drug metabolite clusters using the annotation
based on library matching within the GNPS environment.
Seven clusters contained one or more annotated nodes with
drug related compounds (see Table 1), with some clusters
containing several annotated nodes (indicated in Table 1
with ‘Total annotated nodes’) accumulating to a total of 16
drug related nodes annotated by spectral matching. Six of
those drugs are known antihypertensives. Further inspec-
tion of the annotated nodes revealed that four of them were
correctly matched to a metabolite with the correct mass and
fragmentation spectrum (indicated in Table 1 as ‘correctly
annotated’). The other twelve annotated nodes were partial
matches where the mass of the matched metabolite did not
correspond to the mass of the fragmented metabolite, while
parts of their fragmentation spectra did show high simi-
larity (indicated in Table 1 as ‘related compound’).
Figure 2 shows the example of the ‘verapamil cluster’
that was identified since the GNPS annotation of three of
its nodes included verapamil itself. The fact that this cluster
has fourteen nodes indicates extensive biotransformation in
man. Two previously described C–N–C cleavage metabo-
lites of verapamil (Eichelbaum et al. 1979) could be mat-
ched to spectral data available in MassBank, hence the four
highlighted nodes in Fig. 2 are MSI MI confidence level 2
(see Sect. 2.4.4). The other nodes were annotated using
mass differences to the seed nodes (i.e., the annotated
nodes), which included 176.032 (typical for glucuronida-
tion), 14.015 (typical for methylation), and 16.000 (typical
for hydroxylation), as well as manual inspection of their
fragmentation spectra. Subsequently, key drug-related
fragments were determined based on spectral comparisons
(see Supplementary Table S4). The key fragments were
then used to mine the fragmentation files for more related
drug metabolites omitted by the clustering approach; in
some cases resulting in the additional annotation of drug
metabolites (see Supplementary Table S5).
The verapamil metabolites found by the molecular net-
working show a variety of structures ranging from glu-
curonides, typically larger-sized metabolites, to cleavage
products, typically smaller-sized metabolites, also eluting
at different retention times. Furthermore, it is interesting to
note that seven nodes show high interlinkage in the vera-
pamil cluster, indicating that they share a common sub-
structure causing many edges to interlink the nodes. This
was also observed for the other drug related clusters in
Table 1 (see Sect. 2 in Supplementary Materials, Supple-
mentary Figs. S2–S15 or the Cytoscape session file,
MolecularNetworks_DrugClusters.cys, in the Supplemen-
tary Materials). Furthermore, several different drugs also
Table 1 Number of GNPS annotated nodes in each drug related
cluster, with ‘Parent drug’ representing the annotated parent drug,
‘total annotated nodes’ showing how many nodes had a database hit,
‘correctly annotated’ indicating how many nodes were indeed
matched to the correct drug metabolite (i.e., mass and fragmentation
pattern fitted), and ‘related compound’ means a structurally related
drug metabolite was matched from the in GNPS present fragmenta-
tion libraries such as Massbank
Parent drug Total annotated nodes Correctly annotated Related compound
Clodipogrel 1 1 0
Irbesartan/losartan 3 1 2
Verapamil 3 1 2
Atenolol/bisoprolol 2 1 1
Ranitidine 3 0 3
Metformin 3 0 3
Paracetamol 1 0 1
Total 16 4 12
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cluster together, for example losartan and irbesartan which
relates to their sharing of the sartan substructure that pro-
duces overlapping fragmentation spectra (Lo et al. 1995;
Chando et al. 1998).
Suspected additional drug related clusters were recog-
nized by their highly interlinked topology, and subse-
quently annotated by spectral matching (i.e., to MzCloud,
www.mzcloud.org; or literature reference tables) or by
using the fragmentation annotation software MAGMa
(Ridder et al. 2013) (see the cluster shown in Fig. 3).
Analysis of the metabolites present in all 11 urine extracts
containing spectra of this cluster (the nodes with m/z
313.086 and 271.079 ([M?H]?)) resulted in the top-
ranked candidate structure of paracetamol-mercapturate
(conjugate of paracetamol and N-acetylcysteine) for m/z
313.086—a metabolite of a non-antihypertensive drug.
Further inspection of the fragment annotation revealed
key fragments of paracetamol-mercapturate-like metabo-
lites as shown for the C8H8NO2S fragment in Fig. 3c, d
where a diverse set of sulphur containing paracetamol
conjugates were annotated. The urines that contain these
metabolites also contained paracetamol-O-sulphate and
paracetamol-O-glucuronide confirming paracetamol use
by these patients.
The molecular networking approach thus allows anno-
tation of numerous antihypertensive drugs (and antidiabetic
and histamine antagonists, see Sect. 3.3) in the urine
extracts. Moreover, we observed a high interlinkage
topology for these drug related clusters.
Fig. 2 Verapamil related
cluster: the cluster in the
molecular network that contains
verapamil metabolites. In total,
2 urine extracts contain one or
more verapamil related
metabolites. The four
metabolites that could be
annotated based on spectral
matching, including verapamil
itself, are highlighted in the
cluster and structures are
presented for each of them
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3.2 Molecular networking to analyse drug
metabolite occurrences
The molecular networking approach also allows for quick
comparison of the relative abundance of drug metabolites.
Spectral occurrences in the amlodipine (AML) cluster
(Fig. 4a) were extracted for detailed analysis. Three
annotations in the cluster could be matched to data from
the literature where standards for those metabolites had
been synthesized (Suchanova et al. 2008). This spectral
occurrence approach offers rapid interrogation of the data
in a manner analogous to spectral counting applied in
quantitative proteomics (Bantscheff et al. 2007). In Fig. 4b,
we present the total number of AML-related MS2 spectra
found in the seven urines in which any AML-related
metabolites were found, and in Fig. 4c, the total MS2
spectra found for each AML-related metabolite are shown.
Differences in abundance of the AML-metabolites were
evident in different patients (Fig. 4c), and particular drug
metabolites appear to be well suited for studies based on
spot urine samples to ascertain patient compliance for
taking the prescription drug given their universal appear-
ance in patients while parent compound is not measured
(AML itself was found in just one patient, and then in trace
amounts) (Fig. 4d). Based on the AML-related MS2
spectra, the 422.1 node, containing the oxidized amlodipine
carboxylic acid metabolite (see Fig. 4a), is the most readily
detected metabolite. In order to check how well this MS2
spectral based analysis represents the actual LC–MS peak
abundances, the accurate masses of the node metabolites
Fig. 3 MagMa screenshot
displaying the annotation of
node 313.066 in highly
interlinked cluster (a); b the
fragmentation pattern matched
paracetamol mercapturate
(conjugate of paracetamol and
N-acetylcysteine), which is the
top ranked hit in the results.
c Fragment annotation by
MagMa, the fragment
C8H8NO2S is also highlighted
in the structure of paracetamol
mercapturate (d), encompassing
the paracetamol part of the
conjugate including the sulphur
atom from N-acetylcysteine
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Fig. 4 Amlodipine (AML)
related clusters. The molecular
networking and subsequent
node validation process resulted
in the AML-related clusters in
(a). The structures for those
metabolites that could be
annotated by matching product
ions to literature data are shown
(solid boxes) and the annotation
of a AML metabolite based on
spectral homology and mass
differences is also presented
(dashed box), where mtb is short
for metabolite, Glc for
glucuronide, and Ox for
oxidized. In total, 7 urine
extracts contained one or more
AML metabolites, here
represented in five clusters
based on the presence/absence
of AML metabolites. Spectral
occurrences were obtained from
the molecular network,
b presents the total number of
AML-related spectra in each
urine extract that was included
in the cluster, c presents the
total number of acquired MS2
spectra for each AML related
metabolite, d total over 1 9 106
occurrences for each AML
metabolite, and e shows the
intensities (cts) for each AML
related metabolite extracted
from the LC–MS full scans
using accurate mass and
retention time information
obtained during the node
validation process, including the
accurate mass for the parent
drug amlodipine. An arrow is
drawn to connect the annotated
oxidized amlodipine (AML-
OX) COOH metabolite with the
corresponding peak in plot C
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were used to determine LC–MS peak intensities in the
seven urine extracts. Figure 4d, e shows how the MS2
spectral counting does represent the information obtained
from the LC–MS peaks and thus allows for quick interro-
gation of inter-sample differences.
Irbesartan and losartan are both angiotensin II receptor
antagonists. Both of these parent drugs, and their metabo-
lites, were clustered based on their common sartan [(1H-
tetrazol-5-yl)biphenyl-4-yl] backbone (Fig. 4). The meta-
bolism of irbesartan has been extensively studied using
14C-labelled parent drug to trace its metabolites in urine
(Chando et al. 1998) and eight labelled irbesartan
metabolites in addition to the parent drug itself were found.
The authors used fragmentation data as well as 1D and 2D-
NMR spectra to identify structurally those metabolites as
completely as possible. Comparing their reported elemental
formulas and nominal product ions, we could match two
irbesartan metabolites with confidence (MSI MI level 2)
based on the unique product ions for M1 (C11H19N2O3,
nominal mass 227) and M6 (C11H17N2O2, nominal mass
209). The spectral match for three other metabolites was
ambiguous (MSI MI level 3) and complementary structural
information (such as from NMR) or availability of refer-
ence compounds would be necessary to fully identify those
metabolites. Overall, 4 different masses matched between
our analysis and that of Chando et al., where the co-eluting
hydroxylated losartan metabolites underwent extensive
preparative HPLC to separate them.
Losartan was found in five urine extracts. Its metabolites
were easily discriminated from the irbesartan metabolites
since the chlorine atom in their structure generates a
characteristic isotope pattern in full scan mode. A report on
losartan metabolism (Schmidt and Schieffer 2003) did not
report on mass spectra, but we used the assigned elemental
formulas typically containing six nitrogen atoms and one
chloride atom, to allow matching to an active losartan
metabolite EXP3174, and a ketone derivative of losartan
(Fig. 5). Figure5b, c show the MS2 spectral occurrences
and the abundances obtained from the LC–MS peaks. The
parent drug and a hydroxylated derivative are abundant in
all five urine extracts. Manual inspection of the losartan
nodes further revealed two isomers of EXP3174 (a COOH
metabolite, m/z 437.1487, [M?H]?), (Fig. 5d). The MS2
spectra of the two peaks showed differences in abundances
for drug related product ions (see Supplementary Fig. S1).
Thus, manual inspection of the clusters and nodes
remains important to ensure the presence of one or several
metabolites in one node. The drug metabolism information
obtained through metabolite networking also warrants
further investigation on the metabolism of drugs like
losartan to establish the potential role of the structurally
differential isomers. From Fig. 5, it can be observed that
both the parent drug and a hydroxylated form of losartan
can be used in drug adherence studies, as these are the most
abundant and widely present losartan metabolites detected
in this set of patients.
3.3 Unsupervised clustering also reveals other drug
types and endogenous metabolites in urine
The unsupervised clustering approach not only revealed the
presence of eight antihypertensive drug related clusters
including 10 different drugs, it also clustered metabolites of
other drug types and endogenous urinary metabolites.
Metformin, an antidiabetic, was annotated to a cluster
containing a variety of precursor ions in the nodes. Indeed,
the spectra shared the typical nitrogen-rich product ions of
metformin and the urine extracts containing metformin
were derived from four patients of whom three were
reported to have diabetes, thereby identifying metformin in
a male patient (aged 63) not reported to have diabetes.
Many of the clustered nodes could be tentatively annotated
as metformin conjugates with small organic acids.
Metabolites of another drug-like cluster were found in
three of the urine samples with the metformin metabolites,
and could be annotated as a sulfonylurea type of drug,
consistent with gliclazide based on fragment information
also commonly prescribed to diabetes patients. Another
drug-like cluster was annotated by GNPS with ranitidine, a
histamine H2-receptor antagonist (inhibiting stomach acid
production), with 20 separate metabolites present in one
sample, indicating the extensive metabolism to which this
drug is subject. Ranitidine is available in the UK both as
prescription and over-the-counter formulations. No litera-
ture was found describing such extensive ranitidine meta-
bolism. This finding reveals that common, over-the-counter
drugs that might be in use for other medical reasons can
also be identified and if applied to large studies on drug
compliance and action, will offer an objective approach to
seeking possible drug–drug interaction effects. Finally, two
suspected drug metabolite clusters were annotated with
MSI MI level 4 metabolites showing characteristic frag-
mentation patterns but without annotated core structure.
Altogether, a total of 165 different antihypertensive or
other drug related metabolites were annotated in the urine
extracts: 17 by spectral matching (MSI MI level 2) and 122
by classification based on the clustered fragmentation
patterns (MSI MI level 3). This ultimately led to the
detection of metabolite clusters of 13 different drugs in the
studied urine extracts. All drug metabolites that were
annotated in this study are described in Supplementary
Table S3 with their theoretical masses, elemental formulas,
annotation (with details on database or reference), MSI MI
level, parent drug, and the drug class. A simplified Excel
Table without annotation details is also available (Sup-
plementary Table 3B). Although, in line with standard
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procedures, the urine spot tests are analysed in a blinded
fashion, we can monitor that patient 61 was on losartan and
bisoprolol, that patient 66 administered enalapril, bisopro-
lol, metformin, and likely gliclazide (a sulfonylurea class
drug), and also took paracetamol, and that patient 91 was
on losartan, perindopril, and atenolol, and also took
paracetamol.
Molecular networking also clustered endogenous uri-
nary metabolites based on their fragmentation patterns.
Table 2 lists nine annotated clusters that include different
biological compound classes including acylcarnitines
(carnitine based), glutamine-related metabolites, and tri-
gonelline related compounds. Most of these clusters were
found using the combined fragmentation mode (first
column in Table 2) with the betaine based cluster only
found using the separate fragmentation mode (second
column in Table 2). Trigonelline related compounds can
be found in many plants and trigonelline has a vitamin B
related structure; hence those metabolites could be either
food-derived or endogenous break-down products of
Fig. 5 Sartan (irbesartan and
losartan) related cluster. In total,
5 urine extracts contain 1 or
more losartan metabolites and 1
unique urine extract contains
irbesartan related metabolites.
Nodes representing chlorine
isotopes of losartan metabolites
were removed from the cluster.
a Three losartan and three
irbesartan related metabolites
are highlighted, annotated based
on spectral matching or spectral
homology and mass differences,
where mtb is short for
metabolite. b The total number
of acquired MS2 spectra for
each metabolite or metabolite
group is shown. c The
abundance (cts/s) of losartan
metabolites across the different
urine extracts. Note that the two
437.1487 isomers cause a
relative high spectral counting
(total number of MS2 spectra)
for this metabolite group as a
result of being combined in one
node. d Extracted ion
chromatogram for the m/z
437.1487, showing the two
closely eluting isomers. In
Supplementary Fig. 1, their two
MS2 spectra are displayed
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Vitamin B. In-depth metabolite annotation of all the
clustered nodes of these nine clusters was outside the
scope of this study; however, we did compare the masses
detected in the acylcarnitine cluster with those previously
annotated in a study using fragmentation data (van der
Hooft et al. 2015); and substantial overlap between the
masses was clear. The third column in Table 2 also
showed that of four compound classes, at least one
associated metabolite is present in all 26 urine extracts,
illustrating their wide occurrence in humans. A series of
glutamine containing compounds is one of those clusters
and fragmentation spectra are consistent with a family of
acylglutamines, i.e., glutamine-based analogues of acyl-
carnitines with different acyl chains. Very little literature
exists discussing the existence or roles for acyl glutami-
nes, and yet their abundance and diversity indicates they
may represent a family of molecules with important
metabolic functioning. Molecular networking can clearly
assist in classifying urinary metabolites and aid in the
annotation and identification of endogenous metabolites
as well as xenobiotics.
4 Discussion
The combination of high-resolution untargeted mass
spectrometry data-dependent fragmentation spectra and
molecular networking has enabled the identification of a
multitude of drugs and their metabolites in human urine
samples. With over 5000 MS2 fragmentation scans
obtained in each fragmentation measurement, and 26 urine
fragmentation measurements, the number of MS2 spectra
requiring processing and analysis counts in the tens of
thousands. Advanced spectral analysis tools are needed to
fully exploit the structural information present in frag-
mentation data and the molecular networking approach
clearly offers a means to derive important information from
such large and complex datasets.
Our approach was based on an existing HILIC chro-
matography based metabolomics platform (Creek et al.
2011), thereby focusing on polar and charged urinary
metabolites. No single existing liquid chromatography
platform can separate all drug metabolites efficiently in one
run, and in our approach the majority of drug metabolites
eluted between 3.5 and 4.5 min; however, a considerable
number also elute in the period afterwards. Coupling
HILIC-based liquid chromatography to Orbitrap high res-
olution spectrometry allows for the simultaneous detection
of a wide range of polar urinary compounds in both posi-
tive and negative ionization modes. Our analysis focused
on positive ionization mode which was compatible with
most drugs, bearing several nitrogen atoms and thus easily
ionizing in positive mode. Furthermore, with positive
ionization mode generally resulting in more product ions
per metabolite than negative ionization mode, the occur-
rence of drug related clusters was favoured in positive
ionization mode.
Most reported LC–MS based drug methods are either
focused on structural elucidation of one specific drug and
its major pre-ascertained metabolites in biofluids or on the
detection of multiple drugs through one drug related
metabolite (usually the administrated drug or the active
compound in case of pro-drugs). Our approach offers the
ability to screen for many different types of drugs, irre-
spective of any expectation of their presence. Furthermore
up to 20 different metabolites of a single drug were readily
identified in the case of ranitidine which indicates how this
Table 2 Table describing annotated clusters of non-drug metabolites,
with ‘Compound class’ being the annotated core structure for each
cluster, ‘Nodes in cluster’ being the number of nodes in each
annotated cluster from the combined and separate fragmentation
mode, respectively, and ‘MaxUniqueFileCount’ showing the occur-
rence of the most widely distributed nodes for each cluster
Compound class Nodes in cluster combined
fragmentation mode — POS
Nodes in cluster separate
fragmentation mode — POS
MaxUniqueFileCount No. unique
urine files (# nodes)
Carnitine based 52 52 26 (5), 25 (6)
Glutamine based 18 18 26 (3), 25 (2)
Trigonelline based 12 11 26 (1), 11(1)
Betaine based - 11 12 (4), 8 (1) [POS only]
Steriod skeleton 2 ? 2 12 11 (1), 8 (2)
Pyrriline-CO based 16 9 15 (1), 9 (3)
Pipecolic acid based 20 12 26 (4), 25 (2)
Lysine based 9 7 24 (1), 19 (1)
N containing oxygen rich
substructure
10 10 2 (4), 1 (6)
Total 137 142 N/A
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approach can offer the means to initiate comprehensive
studies into drug metabolism with relative ease.
It was encouraging to observe that many edges (con-
nections between the cluster nodes) displayed typical mass
differences of 176.032 (glucuronidation), 14.015 (methy-
lation), and 16.000 Da (hydroxylation) that are commonly
associated to drug (or xenobiotic) metabolism in man.
Indeed, the described workflow is biased towards heavily
metabolized core structures, since they will appear as dis-
tinct highly interlinked clusters in the molecular network.
However, with more reference data becoming available in
the future (i.e., increasing seed node annotation), the
clusters of two or three drug metabolites may be detected
more easily.
The structural identification of detected metabolites
remains a bottleneck in untargeted metabolomics approa-
ches (Creek et al. 2014; van der Hooft et al. 2013; Li et al.
2013; Roux et al. 2012; Dunn et al. 2013; Kind and Fiehn
2010; Wishart 2011). Generic fragmentation pathways for
a number of antihypertensive and other drugs are available
in the literature (Niessen 2011); however, high-resolution
reference data of drug metabolites is still scarce and the
comparison of fragmentation spectra across different plat-
forms is not always straightforward. Moreover, the avail-
able structural information is often scattered across
databases or tabulated within publications. Many databases
generated by the Pharmaceutical industry are proprietary
and thus not accessible. Mass spectral databases thus
remain far from being a comprehensive representation of
the contents of a given biological extract (Vinaixa et al.
2015; da Silva et al. 2015).
The current study shows that spectral clustering and
matching enhances metabolite annotation and classifica-
tion; however, extensive manual interpretation and vali-
dation remain essential for confident assessment of
metabolite structures. For example, the drug clusters of
the paracetamol mercapturates, enalapril and perindopril,
amlodipine, the sulfonylurea class drug, and quinidine
were annotated using amalgamated information from
published literature values for drug product ions, MagMa
(Fig. 3), or MzCloud spectral matching. Moreover, using
the key fragments for each drug or drug family (see
Supplementary Table S4), 45 additional drug metabolites
were annotated that were not directly represented by a
node within the molecular network. Our approach can
map different classes of drugs and with the expected
growth in spectral databases it certainly has the potential
to group other xenobiotics and endogenous urinary
metabolites as well. In fact, we could annotate a number
of endogenous human metabolite clusters. For example,
the acylcarnitine based cluster contained 52 nodes and of
the masses of the 15 most widely distributed nodes (in
[20 urine extracts present) all but 3 were indeed
previously annotated as acylcarnitines (van der Hooft
et al. 2015). The validation process also identified nodes
that represented specific atomic isotopes (in chlorine-
containing drugs like amlopidine) or adducts with co-
eluting abundant metabolites like urea, which were
removed from further analysis and annotation.
The amlodipine and ARB (sartan-based) drug clusters
were analysed in more detail. For amlodipine, selected
product ions could be matched to those reported from rat
urine metabolites (Suchanova et al. 2006, 2008) alongside
fragmentation data for two chemically synthesised oxi-
dized amlodipine metabolites that we also observed in the
human urine extracts (Suchanova et al. 2006). A study on
14C-labelled amlodipine metabolism in two humans
(Beresford et al. 1988), revealed oxidized amlodipine
metabolites that were excreted in the urine and an abundant
COOH-metabolite of oxidized amlodipine, which matches
well with our results. Our findings, which were derived
with no preconception on which drugs or metabolites
present in the samples, shows how the method can make
important contributions to drug metabolism analysis with-
out any need for bespoke reagents. Moreover, the study
shows that the COOH-metabolite of oxidized amlodipine
could be a better marker for amlodipine intake than the
currently used amlodipine parent drug (Lawson et al.
2015). Losartan and hydroxylated losartan were found to
be the most abundant drug metabolites present in the five
urine samples containing metabolites related to this drug.
Indeed, losartan was detected in plasma for up to 24 h after
intake (Lo et al. 1995), indicating that this drug is excreted
into the urine intact in most people. We found two closely
eluting and related, but discernible isomers. One is likely to
be the active EXP3174 metabolite (McCrea et al. 1999),
and the other a ketone derivative (more analytical work
would be required to confirm their structures). Critically we
can identify differences between patients in the presence of
these isomers, which indicates that the technique can be
used to classify patients based on their ability to metabolise
drugs. This in turn can then be linked to patient response
data and offers the potential to predict patient response.
Our approach not only detected clusters of drug
metabolites, but also biochemically relevant clusters of
endogenous urinary compounds, as is illustrated by a
number of different acyl amino acid families. Difference in
levels of specific acyl amino acids has been directly linked
to metabolic diseases (Chace 2009), and their enhanced
annotation might facilitate future correlations between
phenotypes and metabolites. Since it is also possible to
identify other xenobiotics (e.g. non-antihypertensive drugs
or even food related metabolites, note the impact of
grapefruit juice on losartan pharmacokinetics (Zaidenstein
et al. 2001; Bailey et al. 1998)), the potential to contribute
to understanding drug metabolism and patient response
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may extend far beyond the simple identification of drugs
and metabolites, but enable multidimensional correlation
analysis offering predictive precision medicine. Further-
more, non-declared secondary health problems for which
patients are taking drugs can be more easily spotted.
5 Conclusions
Medication nonadherence is a common problem with up to
50 % of patients not adherent to long-term medications.
However, drug adherence phenotype is not a simple trait
and different tools are required to differentiate subtypes as
this has implications on how nonadherence is treated
(Marcum et al. 2013). There are limitations to the currently
used methods of testing drug adherence and newer methods
that can detect not only drug adherence agnostically but
also reveal underlying physiology are essential. This study
reveals the power of combining untargeted urinary meta-
bolomics with molecular networking to guide the inter-
pretation of large numbers of urine metabolite
fragmentation spectra and identify, in an untargeted way,
many drugs and metabolites associated with them. As a
result, we report the key fragments we observed for each
drug cluster based on spectral comparisons as well as an
annotated table of all the validated metabolites in the
clusters. In addition to offering utility in drug compliance
testing (where parent drug or abundant metabolites can
indicate whether patients have been taking the drugs) the
approach also enables discrimination of metabolites in
different people. If combined with large studies where
treatment outcomes are also considered it may be possible
to correlate certain metabolites with patient response to
drug and thus offer novel tests to guide precision patient
centred medicine. Moreover, the approach can also detect
other drugs irrespective of prior knowledge of their pres-
ence which can also offer insights into drug–drug interac-
tions. The expected increase in coverage of spectral
databases and increasingly available in silico tools for
metabolite annotation based on fragmentation data will aid
in identification of drug metabolites not currently present in
mass spectral libraries. Paracetamol-mercaptures were
successfully annotated in our study with the aid of the in
silico fragmenter MAGMa. Since endogenous metabolites
are detected in the same datasets, the approach may detect
roles for these in drug response and metabolism as well.
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